May 2024

• Octave® Bioscience, Inc. Announces Publication in Nature Communications

April 2024

• Foralumab found to ease fatigue in SPMS patients in access program

• Chitnis Makes Strides in Research and Care for Patients with Multiple Sclerosis

March 2024

• Understanding the Underlying Progression of Multiple Sclerosis

• Question and Answer about Neurofilament Light Chain and Other MS Biomarkers

February 2024

• The CLIMB Study

• Monitoring Patients After a Change in Treatment Regimen

• Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease

• The CLIMB Study

January 2024

• Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care

• Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions

• The Value of Biomarker in Multiple Sclerosis

December 2023

• Dosing begins in Phase 2a trial of foralumab nasal spray for SPMS

• Insights Into the Molecular Pathogenesis of Progression in Multiple Sclerosis

• Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

September 2023

• Octave’s blood test accurately captures MS disease activity: Study

August 2023

• Octave® Bioscience, Inc. Announces Publication of Clinical Validation Study Results of its Novel, Multivariate Multiple Sclerosis Disease Activity (MSDA) Blood Test

• FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease

June 2023

• What makes multiple sclerosis worse, and how to make it better

• The Potential of Targeting Anti-CD3 in Progressive Multiple Sclerosis: Tanuja Chitnis, MD

• Decreased Microglial Activation Observed in Foralumab-Treated Patients With Secondary Progressive MS

• Microglial activation reduced in 5 of 6 SPMS patients on nasal foralumab

March 2023

• Risk for MS in Children Often Missed

• Children at risk of multiple sclerosis often go undetected in early stages

• Tiziana Announces Planned Phase 2 Study of Foralumab in Progressive Multiple Sclerosis

• Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab

January 2023

• Researchers Uncover a Connection Between Multiple Sclerosis Lesions and Depression

• Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab

• EDSS Score Drop of 1 Point Seen in 2nd SPMS Patient on Foralumab

December 2022

• Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022

• Alzheimer's vaccine: Nasal spray trial shows promise, researchers say

November 2022

• Tiziana Planning 2023 Launch of Phase 2 Foralumab Trial in SPMS

• Expanded Access Program of Nasal Foralumab Enrolls 4 SPMS Patients

October 2022

• Fingolimod Continues to Outperform Interferon in Long-Term PARADIGMS Study of Pediatric MS

• Tiziana Life Sciences Plans IND for Phase 1 Study of Intranasal Foralumab in Alzheimer Disease

September 2022

• Second SPMS Patient Given Foralumab Continues to Improve

• Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab

• BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

• Could an Intranasal Vaccine Transform Alzheimer’s Prevention and Treatment?

August 2022

• Expert Voices: Understanding Pediatric Multiple Sclerosis Research and Care

June 2022

• Baker-Polito Administration Announces $5.6 Million in Life Sciences Funding to Drive Innovation in Data Science, Drug Delivery, and Women’s Health

• Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD

• NeuroVoices: Tanuja Chitnis, MD, on Targeting Anti-CD3, Other Biomarkers in Progressive Multiple Sclerosis

• Episode 65: 2022 CMSC Annual Meeting Highlights

• 2nd SPMS Patient Sees Clinical Gains With Foralumab Treatment

• Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting

May 2022

• CDMRP-Funded Research Leads to FDA Breakthrough Device Designation for MS Blood Biomarker Test ---- New Hope for Early Diagnosis, Effective Treatment

• Episode 247: Biomarkers Can Help Diagnose MS, Predict MS, and Telegraph MS Progression with Dr. Tanuja Chitnis

January 2022

• 2nd Patient to Get Foralumab Nasal Spray After Promising First Data

• Tiziana Life Sciences Ltd.: Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive

December 2021

• BWH Researchers Launch First-Ever Human Trial for Alzheimer’s Nasal Vaccine

• Alzheimer’s Nasal Vaccine, Protollin, in Clinical Trials

• Further Study Needed for Teriflunomide in Children With Relapsing MS

• Aubagio Reduces Lesions in Children in Trial, but Relapse Data Troubled

• Sunshine may shield children, young adults from MS

November 2021

• In children with multiple sclerosis, teriflunomide tempers lesion growth

• The inside story of the search for an Alzheimer’s vaccine

May 2021

• Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers

April 2021

• SPMS Patient First To Be Treated With Antibody Given via Nasal Spray

March 2021

• Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program

• BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS 

February 2021

• ACTRIMS 2021 | Serum neurofilament levels are associated with health outcomes and resource use in MS

• ACTRIMS 2021 | MS disease stage modulates the relationship between serum neurofilament light and age

• ACTRIMS 2021 | Changing approaches to cognitive assessment in MS

• ACTRIMS 2021 | Determining the optimal treatment strategy in MS

• ACTRIMS 2021 | Ensemble learning methods predict disease course in MS

January 2021

• Expert analysis: Treating MS with autologous hematopoietic stem cell transplant

December 2020

• Smartwatches Show Impact of Stay-At-Home Practices on MS Patients

September 2020

• #MSVirtual2020 – Long-term Aubagio Use Seen to Lower Relapse Risk for Children

August 2020

• BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis (MS)

• #MSVirtual2020 – MRI Changes Can Reflect Function in Progressive MS, Study Says

May 2020

• Department of Defense: Congressionally Directed Medical Research Programs

• EAN 2020 | Teriflunomide shows benefits in children with relapsing forms of MS

• EAN 2020 | TERIKIDS study: teriflunomide in pediatric patients with relapsing MS

• EAN 2020 | Pediatric MS: where does research need to move?

• EAN 2020 | Pediatric versus adult multiple sclerosis

• EAN 2020 | Emerging research in pediatric MS

April 2020

• “Ask An MS Expert” Webinar Series - RealTalk MS Podcast: COVID-19 Update and the Stimulus CARES Act — with Dr. Tanuja Chitnis, Steffany Stern, and Steve Nissen

March 2020

• Final Site Announced in Phase 2 Trial Testing NurOwn in Progressive MS

February 2020

• Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial

• Multiple Sclerosis Made Me Stronger

January 2020

• Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteers

December 2019

• From Flame to Inflammation: How Smoking Likely Worsens MS

• Year in Review: Multiple Sclerosis

November 2019

• Food Allergies & Disease Activity in Multiple Sclerosis

September 2019

• Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers

August 2019

• Obesity in Younger MS Patients Linked to Poor First-Line Therapy Response

April 2019

• Mineral deficiencies may not have bearing on MS progression, study concludes

March 2019

• Dr Tanuja Chitnis Details How Clinicians Are Understanding Patients' Overall Disease Course in MS

• Can MS Treatment Be Stopped? — Pendulum keeps swinging on risks from drug discontinuation

• #ACTRIMS2019 – Forum Leaders Discuss: ‘Will There Be a Cure for MS?’

February 2019

• Stem Cell Blood Transfusion Slows the Progression of Relapsing-Remitting Multiple Sclerosis

• Food allergies and multiple sclerosis: New link

• Strange link between food allergies and multiple sclerosis bolstered by new study

December 2018

• Food Allergies Tied to MS Relapses

September 2018

• New Drug Could Help Kids With MS

• Gilenya More Effective Than Avonex in Lowering Relapse Rates, New Lesions in Children with Relapsing MS, Phase 3 Trial Shows

June 2018

• Drug Promises Hope for Children with Relapsing MS